Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Enhertu
Biotech
Boehringer flexes staying power of HER2-mutant lung cancer med
Tyrosine kinase inhibitor zongertinib has an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said.
Zoey Becker
Apr 28, 2025 9:00am
Roche companion test moves into HER2-ultralow breast cancer
Feb 4, 2025 12:00pm
Boehringer, Bayer advance lung cancer meds toward Enhertu battle
Sep 9, 2024 4:43pm
AstraZeneca places next ADC bet on in-house pipeline
Feb 21, 2024 8:00am
Jazz auditioning for new bandmates in hot M&A market
Jun 6, 2023 9:35am
Eisai inks Bliss ADC deal to challenge AstraZeneca blockbuster
May 8, 2023 8:55am